These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
561 related articles for article (PubMed ID: 35041491)
1. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. Du X; Darcy PK; Wiede F; Tiganis T Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491 [TBL] [Abstract][Full Text] [Related]
2. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy. Mo F; Duan S; Jiang X; Yang X; Hou X; Shi W; Carlos CJJ; Liu A; Yin S; Wang W; Yao H; Yu Z; Tang Z; Xie S; Ding Z; Zhao X; Hammock BD; Lu X Signal Transduct Target Ther; 2021 Feb; 6(1):80. PubMed ID: 33627635 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model. Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J Front Immunol; 2024; 15():1362904. PubMed ID: 38855110 [TBL] [Abstract][Full Text] [Related]
4. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399 [TBL] [Abstract][Full Text] [Related]
5. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A Front Immunol; 2021; 12():665970. PubMed ID: 34475869 [TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice. Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636 [TBL] [Abstract][Full Text] [Related]
8. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040 [TBL] [Abstract][Full Text] [Related]
9. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses. Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066 [TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795 [TBL] [Abstract][Full Text] [Related]
11. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy. Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403 [TBL] [Abstract][Full Text] [Related]
12. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors. Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140 [TBL] [Abstract][Full Text] [Related]
13. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. Wiede F; Lu KH; Du X; Liang S; Hochheiser K; Dodd GT; Goh PK; Kearney C; Meyran D; Beavis PA; Henderson MA; Park SL; Waithman J; Zhang S; Zhang ZY; Oliaro J; Gebhardt T; Darcy PK; Tiganis T EMBO J; 2020 Jan; 39(2):e103637. PubMed ID: 31803974 [TBL] [Abstract][Full Text] [Related]
14. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290 [TBL] [Abstract][Full Text] [Related]
15. Deletion of PTPN22 improves effector and memory CD8+ T cell responses to tumors. Brownlie RJ; Wright D; Zamoyska R; Salmond RJ JCI Insight; 2019 Jul; 5(16):. PubMed ID: 31335326 [TBL] [Abstract][Full Text] [Related]
16. OT-I TCR Transgenic Mice to Study the Role of PTPN22 in Anti-cancer Immunity. Brownlie RJ; Zamoyska R; Salmond RJ Methods Mol Biol; 2024; 2743():81-92. PubMed ID: 38147209 [TBL] [Abstract][Full Text] [Related]
17. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710 [TBL] [Abstract][Full Text] [Related]
18. Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors. Nipper AJ; Warren EAK; Liao KS; Liu HC; Michikawa C; Porter CE; Wells GA; Villanueva M; Brasil da Costa FH; Veeramachaneni R; Villanueva H; Suzuki M; Sikora AG Immunohorizons; 2024 Aug; 8(8):598-605. PubMed ID: 39225630 [TBL] [Abstract][Full Text] [Related]
19. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C Front Immunol; 2020; 11():99. PubMed ID: 32117253 [TBL] [Abstract][Full Text] [Related]
20. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]